R & D

U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

 This material is intended to notify the press release issued on March 7 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.